Related Experiment Video

Updated: Jul 5, 2025

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay
09:03

Author Spotlight: Investigating Angiogenesis and Vessel Permeability Through a Modified Matrix Gel Plug Assay

Published on: June 30, 2023

954

Novel Products as Promising Therapeutic Agents for Angiogenesis Inhibition

Shaheen Sultana1, Shahnaz Sultana2, Shehla Nasar Mir Najib Ullah3

  • 1Department of Pharmaceutics, IIMT College of Pharmacy, Uttar Pradesh 201310, India.

Current Drug Delivery
|January 11, 2024
PubMed
Abstract

Insights

Anti-angiogenesis agents are crucial for controlling cancer growth by inhibiting new blood vessel formation. This review details novel anti-angiogenic agents beneficial for cancer treatment.

Area of Science:

  • Oncology
  • Biomedical Sciences

Background:

  • Angiogenesis, the formation of new blood vessels, is vital for development, wound healing, and tumor growth.
  • Carcinogenesis involves complex factors contributing to angiogenesis, necessitating targeted therapeutic strategies.
  • Anti-angiogenesis agents offer a promising approach to impede tumor progression by disrupting tumor vascularization.

Purpose of the Study:

  • To provide a comprehensive overview of factors driving angiogenesis during cancer development.
  • To highlight the role of anti-angiogenesis agents in cancer treatment.
  • To review novel anti-angiogenic agents for optimizing cancer control strategies.

Main Methods:

  • Review of existing research on angiogenesis and carcinogenesis.
  • Analysis of data supporting the efficacy of anti-angiogenic agents.
  • Compilation of information on various angiogenic inhibitors for cancer therapy.

Main Results:

  • Evidence from multiple studies confirms the beneficial effects of anti-angiogenic agents in cancer treatment.
  • Novel anti-angiogenic inhibitors have shown potential in reducing morbidity and mortality associated with carcinomas.
  • The summarized data underscore the importance of anti-angiogenesis in managing cancer.

Conclusions:

  • Novel anti-angiogenic agents are pivotal in controlling carcinogenesis.
  • Developing comprehensive treatment strategies combining anti-angiogenic agents is essential for effective cancer management.
  • Targeting angiogenesis remains a key focus in the fight against cancer.
Keywords:
AngiogenesisCOX.CRCantiangiogenic agentscancercarcinogenesis

More Related Videos

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells09:03

Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells

Published on: November 23, 2014

9.8K
Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia07:48

Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia

Published on: June 8, 2019

8.7K

Related Concept Videos

Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
5.5K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.6K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
183
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
432